Sophie Agaugué

Sophie Agaugué has a diverse work experience in the field of research and development, with expertise in immuno-oncology. Their most recent position is as the VP Preclinical Research at Imcheck Therapeutics, a role they have held since January 2023. Prior to this, they served as the Preclinical Discovery Director at the same company from November 2021 to January 2023. Before joining Imcheck Therapeutics, Sophie worked at Celyad as an R&D manager from December 2016 to November 2018, and as an R&D project leader from May 2016 to December 2016. Sophie also gained experience at THERAVECTYS as a senior scientist in immuno-oncology from January 2014 to March 2016. Earlier in their career, Sophie worked as a junior researcher at INSERM from September 2010 to December 2013 and as a junior researcher at CEA from February 2008 to February 2010. Sophie started their professional journey as a postdoctoral researcher at the University of Genoa, where they worked from January 2006 to January 2008.

Sophie Agaugué obtained their Ph.D. in Immunology from École normale supérieure de Lyon, where they studied from 2001 to 2005. Prior to that, they pursued their Master's degree in Biology with a focus on Physiology and Nutrition at Université de Bourgogne from 1996 to 2000. In addition to their educational qualifications, Sophie Agaugué has also obtained a certification known as "Habilitation à l'expérimentation animale de niveau I," although details regarding the institution, month of obtaining, and year of obtaining are not provided.